A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma

Cancer Gene Therapy

Volumn 10, Issue 4, 2003, Pages 251-259

  Khorana, Alok A ^a   Rosenblatt, Joseph D ^a,d   Sahasrabudhe, D M ^a   Evans, T ^a   Ladrigan, M ^a   Marquis, D ^a   Rosell, K ^a   Whiteside, T ^b   Phillippe, S ^c   Acres, B ^c   Slos, P ^c   Squiban, P ^c   Ross, M ^c   Kendra, K ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c TRANSGENE S A   (France)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Interferon gamma; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PACLITAXEL; TEMOZOLOMIDE; TG 1041; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BEAM THERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; ERYTHEMA; FATIGUE; FEMALE; FEVER; GENE TRANSFER; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INJECTION PAIN; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR NECROSIS; VIRUS REPLICATION;

ADENOVIRIDAE; ADULT; AGED; BETA 2-MICROGLOBULIN; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; INTERLEUKIN-6; MALE; MELANOMA; MIDDLE AGED;

ADENOVIRIDAE;

EID: 0037385454     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700568     Document Type: Article

References (46)

1. Isaacs A, Lindenmann J. Virus interference. 1. The interferon. Proc R Soc Lond Biol Sci. 1987;5:429-438.
2. Weber JS, Rosenberg SA. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988;48:5818-5824.
3. Boyer CM, Dawson DV, Neal SE, et al. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res. 1989;49:2928-2934.
4. Nistico P, Tecce R, Giacomini P, et al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res. 1990;50:7422-7429.
5. Beniers AJ, Peelen WP, Debruyne FM, et al. HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer. 1991;48:709-716.
6. Restifo NP, Esquivel F, Asher AL, et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol. 1991;147:1453-1459.
7. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers deficient in a antigen processing. J Exp Med. 1993;177:265-272.
8. Carrel S, Schmidt-Kessen A, Giuffre L. Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol. 1985;15:118-123.
9. Guadagni F, Roselli M, Schlom J, et al. In vitro and in vivo regulation of human tumor antigen expression by human recombinant interferons: a review. Int J Biol Markers. 1994;9:53-60.
10. Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors. Science. 1985;230:777-783.
11. Adams DO, Hamilton TA. The cell biology of macrophage activation. Annu Rev Immunol. 1984;2:283-318.
12. Baratin M, Ziol M, Romieu R, et al. Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther. 2001;8:193-202.
13. Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;189:1343-1354.
14. Schreiber RD, Celada A. Molecular characterization of interferon gamma as a macrophage activating factor. Lymphokines. 1985;11:87-118.
15. Seliger B, Hammers S, Hohne A, et al. IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res. 1997;3:573-578.
16. White CA, Thomson SA, Cooper L, et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells. Int J Cancer. 1998;75:590-595.
17. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994;153:1697-1706.
18. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495-521.
19. Brunda MJ. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
20. Coughlin CM, Salhany KE, Gee MS, et al. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity. 1998;9:25-34.
21. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1-8.
22. Keane MP, Belperio JA, Arenberg DA, et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol. 1999;163:5686-5692.
23. Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol. 2000;165:5269-5277.
24. Creagan ET, Loprinzi CL, Ahmann DL, et al. A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma. Cancer. 1988;62:2472-2474.
25. Osanto S, Jansen R, Naipal AM, et al. In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma. Int J Cancer. 1989;43:1001-1006.
26. Kurzrock R, Talpaz M, Kantarjian H, et al. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood. 1987;70:943-947.
27. Windbichler GH, Hausmaninger H, Stummvoll W, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138-1144.
28. Kim CJ, Taubenberger JK, Simonis TB, et al Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996;19:50-58.
29. Porgador A, Bannerji R, Watanabe Y, et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. J Immunol. 1993;150:1458-1470.
30. Lusky M, Grave L, Dieterle A, et al. Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. J Virol. 1999;73:8308-8319.
31. Slos P, DeMeyer M, Andre M. Intratumoral delivery of interferon-gamma cDNA with an adenoviral vector in combination with systemic chemotherapy: pre-clinical studies in murine models. Cancer Gene Ther. 2000;7:80-81.
32. Schiller JH, Pugh M, Kirkwood JM, et al. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996;2:29-36.
33. Romero P, Pittet MJ, Valmori D, et al. Immune monitoring in cancer immunotherapy. Ernst Schering Res Found Workshop. 2000;30:75-97.
34. Deichmann M, Benner A, Waldmann V, et al. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res. 2000;19:301-307.
35. Grimm EA, Smid CM, Lee JJ, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res. 2000;6:3895-3903.
36. de Metz J, Hack CE, Romijn JA, et al. Interferon-gamma in healthy subjects: selective modulation of inflammatory mediators. Eur J Clin Invest. 2001;31:536-543.
37. Martinetti A, Seregni E, Belli F, et al. Evaluation on serum 2′-5′oligoadenylate synthetase (2′-5′oligoAS) and beta 2 microglobulin (B2 M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A. Anticancer Res. 1998;18:2027-2030.
38. Fujii S, Huang S, Fong TC, et al. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther. 2000;7:1220-1230.
39. Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cell activity. Nature. 1981;291:335-338.
40. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, et al. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984;160:1147-1169.
41. Malkovsky M, Loveland B, North M, et al. Recombinant interleukin-2 directly augments the cylotoxicity of human monocytes. Nature. 1987;325:262-265.
42. Itoh K, Shiiba K, Shimizu Y, et al. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma). J Immunol. 1985;134:3124-3129.
43. Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst. 1988;80:1393-1397.
44. McAdam A, Pulaski B, Harkins S, et al. Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann N Y Acad Sci. 1993;690:349-351.
45. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol. 1989;143:1210-1214.
46. Agah R, Malloy B, Sherrod A, et al. Successful therapy of natural killer-resistant pulmonary metastases by the synergism of gamma-interferon with tumor necrosis factor and interleukin-2 in mice. Cancer Res. 1988;48:2245-2248.